Anika Therapeutics (ANIK) Non-Current Deffered Revenue (2010 - 2016)

Anika Therapeutics (ANIK) has reported Non-Current Deffered Revenue for 7 consecutive years, with $48000.0 the latest figure, recorded in Q4 2016.

• On a quarterly basis, Non-Current Deffered Revenue fell 27.27% year-over-year to $48000.0 in Q4 2016; TTM through Dec 2016 was $48000.0, a 27.27% decrease from a year earlier, with the FY2016 full-year figure at $48000.0, down 27.27% from the prior year.
• Non-Current Deffered Revenue was $48000.0 for Q4 2016 at Anika Therapeutics, down from $59000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $4.3 million in Q1 2012 and troughed at $48000.0 in Q4 2016.
• A 5-year average of $1.1 million and a median of $79940.5 in 2015 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue plunged 97.21% in 2014 and surged 30.74% in 2015, its largest moves.
• Over 5 years, Non-Current Deffered Revenue stood at $2.2 million in 2012, then dropped by 4.54% to $2.1 million in 2013, then slumped by 95.04% to $102000.0 in 2014, then tumbled by 35.29% to $66000.0 in 2015, then fell by 27.27% to $48000.0 in 2016.
• The last three Non-Current Deffered Revenue figures came in at $48000.0 (Q4 2016), $59000.0 (Q3 2016), and $56000.0 (Q2 2016), per Business Quant data.